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Regular Wine Consumption in Chronic Heart Failure. Impact on Outcomes, Quality of Life, and 
Circulating Biomarkers 
 
Franco Cosmi, MD; Paola Di Giulio, MSc; Serge Masson, PhD; Andrea Finzi, MD; 
Rosa Maria Marfisi, MS; Deborah Cosmi, MD; Marco Scarano, ScD; Gianni Tognoni, MD; 
Aldo P. Maggioni, MD; Maurizio Porcu, MD; Silvana Boni, MD; Giovanni Cutrupi, RN; 
Luigi Tavazzi, MD; Roberto Latini, MD; on behalf of the GISSI-HF Investigators 
Background—Moderate, regular alcohol consumption is generally associated with a lower risk of 
cardiovascular events but data in patients with chronic heart failure are scarce. We evaluated the 
relations between wine consumption, health status, circulating biomarkers, and clinical outcomes in 
a large Italian population of patients with chronic heart failure enrolled in a multicenter clinical 
trial. 
Methods and Results—A brief questionnaire on dietary habits was administered at baseline to 6973 
patients enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza 
Cardiaca-Heart Failure (GISSI-HF) trial. The relations between wine consumption, fatal and 
nonfatal clinical end points, quality of life, symptoms of depression, and circulating biomarkers of 
cardiac function and inflammation (in subsets of patients) were evaluated with simple and 
multivariable-adjusted statistical models. Almost 56% of the patients reported drinking at least 1 
glass of wine per day. After adjustment, clinical outcomes were not significantly different in the 
predefined 4 groups of wine consumption. However, patients with more frequent wine consumption 
had a significantly better perception of health status (Kansas City Cardiomyopathy Questionnaire 
score, adjusted P<0.0001), less frequent symptoms of depression (Geriatric Depression Scale, 
adjusted P=0.01), and lower plasma levels of biomarkers of vascular inflammation (osteoprotegerin 
and C-terminal proendothelin-1, adjusted P<0.0001, and pentraxin-3, P=0.01) after adjusting for 
possible confounders. 
Conclusions—We show for the first time in a large cohort of patients with chronic heart failure that 
moderate wine consumption is associated with a better perceived and objective health status, lower 
prevalence of depression, and less vascular inflammation, but does not translate into more favorable 
clinical 4-year outcomes. 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT0033633. 
Alcohol consumption and its effect on health is a complex topic largely influenced by nationality, 
ethnicity, age, social, and family status of patients forming study populations. Wine can be 
considered a unique example of this complexity because it is customarily a daily component of a 
standard meal in some areas and populations, but only an occasional event in others, and formally 
forbidden because of religious constraint in large populations. In the absence of randomized 
controlled trials, observational studies suggest that moderate and regular alcohol consumption but 
not binge drinking1 is associated with lower risk of cardiovascular events, particularly myocardial 
infarction,2 and incident heart failure (HF).3 Moreover, in 2006, the AHA suggested that after a 
cardiovascular event patients may continue drinking moderate amounts of alcohol, if they already 
did before.4 The bulk of evidence for a protective effect of moderate wine intake on incident 
cardiovascular events comes from studies in the general population without cardiovascular disease 
or in hypertensive, post myocardial infarction (MI), diabetic patients.3–9 Recently, data have been 
obtained within the INTERHEART case-control study in >27 000 individuals from 52 countries 
showing that this protection may not be effective across different countries.2 A significantly lower 
incidence of all-cause deaths and cardiovascular events was reported in 11 248 Italian post MI 
patients enrolled in the GISSI Prevenzione trial.10 However, the issue is still controversial, as there 
are no controlled prospective trials.11,12 
Four studies previously addressed this subject in patients with HF or left ventricular (LV) 
dysfunction: 6313 patients from the Studies of Left Ventricular Dysfunction (SOLVD) trial,13 2231 
post MI patients from the Survival and Ventricular Enlargement (SAVE) trial,8 449 male US 
physicians,14 and 117 Italian patients aged ≥65 years.15 In chronic HF, dietary indications and 
control are of paramount importance but, at the same time, different pathophysiologic determinants 
and variability in clinical profiles are unavoidable confounding factors.16 
GISSI-HF, a double-blind randomized trial found that n-3 polyunsaturated fatty acids (1 g/d), but 
not rosuvastatin (10 mg/d), slightly but significantly reduced mortality and hospital admissions for 
cardiovascular reasons in patients with symptomatic chronic HF of any cause.17,18 Because all 
patients completed a brief diet questionnaire at baseline, including daily wine, beer, and spirits 
intake, we investigated the possible relationship between the latter and the clinical outcome 
indicators, with the aim of verifying whether the benefit of moderate wine consumption shown in a 
population of post-MI patients from GISSI Prevenzione applied also to patients with symptomatic 
chronic HF. In addition, in 2 subgroups of patients from the same study, we assessed the relations 
between wine consumption and several circulating biomarkers or indicators of health status 
perception. This enabled us to search for relations between wine, outcomes, biohumoral, and 
behavioral factors in a contemporary population of patients with chronic HF with any level of LV 
ejection fraction (LVEF). 
 
Methods 
The GISSI-HF trial was a randomized, double-blind, placebo-controlled, multicenter study that 
enrolled 6975 patients with clinical evidence of chronic, stable HF (New York Heart Association 
II–IV), of any cause and level of LVEF.17,18 The trial investigated the effect of adding 1 g of n-3 
polyunsaturated fatty acids per day or placebo to standard therapy in patients with moderate-to-
severe HF. In the prospectively planned biomarker substudy, blood samples were collected at 
randomization and 3 months later from 1235 patients recruited in 51 clinical centers. Investigators 
participated on a voluntary basis and ensured that all eligible patients would have been enrolled in 
the present substudy, to minimize selection bias. The study was approved by the local ethics 
committee and informed consent was obtained from all patients before the study started. The other 
predefined substudy was quality of life (QoL), depression, and cognitive function, which enrolled 
1465 patients to whom questionnaires on QoL, depression, and cognitive function were serially 
administered by attending nurses.19 
 
Wine Consumption. In the main GISSI-HF study, a brief questionnaire on dietary habits was 
administered to each patient at study entry. Wine consumption was divided into 4 categories, such 
as patients who did not drink wine, those who drank it occasionally, and those with low to moderate 
(1–2 glasses per day) and high (≥3 glasses per day) consumption. In the general study population, 
baseline data included patient’s characteristics, cardiovascular risk factors, medical history, causes 
and New York Heart Association class of HF, physical examination and medical treatment. Primary 
end points were total mortality, cardiovascular mortality and hospital admissions, total and for 
cardiovascular reasons, specifically for worsening HF, arrhythmias, myocardial infarction, and 
stroke. 
 
Health Status Perception and Depression.  The validated Italian version of the Kansas City 
Cardiomyopathy Questionnaire20 was used to define the perception of health status. This specific 
23-item health status measure encompasses several domains, including physical limitations, 
symptoms (frequency, severity, and recent changes) self-efficacy, social interference, and 
QoL.21The summary score ranges from 0 to 100, higher scores denoting better health. Health status 
was defined as good (76–100), fair (51–75), poor (26–50), and worst (0–25). The Geriatric 
Depression Scale is a 15- item well-validated questionnaire that measures emotional factors in 
depression.22 Each yes/no item corresponds to a depressive symptom. 
Subjects with 5 to 8 symptoms were considered to have mild depression and those with >9 
symptoms moderate-to-severe depression. 
 
Circulating Biomarkers 
In the subgroup of 1235 patients enrolled in the biological substudy, a blood sample was collected 
at randomization; EDTA-plasma was stored at −70°C in a centralized biological repository. The 
circulating levels of adiponectin, high-sensitivity C-reactive protein, pentraxin-3 (PTX3), 
osteoprotegerin, N-terminal pro B-type natriuretic peptide, midregional proatrial natriuretic peptide, 
high-sensitivity cardiac troponin T, midregional proadrenomedullin, C-terminal provasopressin 
(copeptin), mannose-binding lectin, and C-terminal proendothelin- 1 were measured, blind, in a 
central laboratory, as previously reported.23–27 
Statistical Analyses 
All the statistical analyses were done on the imputed data set. A multiple imputation technique 
based on a Markov chain Monte Carlo approach28 was used to estimate the missing values for each 
missing data point. For most variables, ≈1% of the data were missing. However, data were missing 
in 9.5% of the study population for fibrinogen, 5.9% for bilirubin, 4.2% for uricemia, 4.1% for low-
density lipoprotein-cholesterol, 3.5% for high-density lipoprotein cholesterol, and 3.0% for CK 
total. Trends across categories were analyzed using respectively the Cochran–Armitage trend tests 
and linear regression analysis for categorical and continuous variables. Cox proportional hazard 
models were used to evaluate the independent associations between wine intake and outcome 
events. Hazard ratios were evaluated in an unadjusted model and then in an adjusted one for major 
potential risk factors based on biological plausibility and associations with exposures/outcomes in 
the present population, for example, demographic, clinical, and lifestyle risk factors. Trends in 
hazard ratios across categories of wine consumption were examined using the variable as 
continuous (eg, coded 0, 1, and 2). The Geriatric Depression Scale score and the Kansas City 
Cardiomyopathy Questionnaire score were expressed as median (interquartile range) and the 
median test was used for their analysis across wine consumption categories. Survival curves were 
adjusted by Cox-regression according to corrected group prognosis method. This method calculates 
the survival curve for each unique combination at all levels of the covariates with a Cox model and 
obtains the adjusted survival curve as a weighted average of those individual curves, in which 
weights are based on the sample sizes in each combination.29,30 
All probability values are 2-sided. All computations used the SAS statistical package (SAS Institute 




Patients’ Characteristics in Relation to Wine Consumption 
The patients declared a low consumption of alcoholic beverages other than wine: 2.4% drank at 
least 1 glass of beer per day, whereas only 1.0% drank 1 glass of spirits. For this reason, we limited 
our main analyses to wine consumption. The distribution of wine consumption of the 6973 patients 
in the GISSI-HF study is shown in Table 1. Age showed no specific trends across groups, although 
the difference between wine consumption groups reached statistical significance. Among 
cardiovascular risk factors, smoking was positively correlated with wine consumption and the 
incidence of chronic obstructive pulmonary disease and neoplasia was higher in groups with higher 
wine consumption; an inverse correlation was observed with history of hypertension. Wine 
consumption was positively associated with a more favorable New York Heart Association 
functional class. Hospital admission in the year before study entry or a history of diabetes mellitus 
was more frequent in patients with no wine consumption. These clinical characteristics were 
consistent with greater severity of HF in patients who never or seldom drank wine, as evidenced 
by physical examination and more frequent treatment with agents, such as angiotensin-converting 
enzyme inhibitors, angiotensin-receptor blockers, diuretics, spironolactone, digitalis, and nitrates. 
Among laboratory values, hemoglobin and glomerular filtration rate were positively correlated with 
increasing frequencies of wine consumption (Table 1). In the absence of a statistically significant 
difference in history or presence of atrial fibrillation, oral anticoagulant agents and amiodarone 
were prescribed significantly more often to wine consumers. 
Wine Consumption and Outcomes 
Clinical events during the 3.9-year follow-up showed a lower incidence in patients with the highest 
wine consumption, with 1 exception, all-cause hospitalizations, which were somewhat more 
frequent in the ≥3 glasses of wine/d group (Table 2). Nonetheless, after adjustment for confounders, 
the differences were no longer significant for any of the clinical outcomes (Table 3). Adjusted 
survival curves by wine consumption categories are presented in Figure 1. Two interaction terms 
were added to the Cox multivariable models, rosuvastatin × wine consumption and n-3 
polyunsaturated fatty acids × wine consumption: interactions with rosuvastatin, but not with n-3 
polyunsaturated fatty acids were statistically significant for both all-cause death and the combined 
end point (Table 3). In other words, the analysis of the direction of the interaction suggests that 
rosuvastatin tended to be associated with worse outcomes than placebo in patients drinking wine, 
than in those not drinking it at all or just occasionally. 
QoL and Depression Substudy 
The distribution of wine consumption of the 1465 patients participating in the QoL, depression, and 
cognitive function substudy is shown in Table 4. The characteristics of this subpopulation of GISSI-
HF were similar to those of the main study population in terms of medical history, clinical 
presentation, and pharmacological treatment.17 Kansas City Cardiomyopathy Questionnaire score 
showed a significant correlation between wine consumption and better health status perception 
(P<0.0001), so that patients with a score <50 (poor or worst) were 21.0% in those who never drank, 
while they were only 7.4% in those drinking at least 3 glasses of wine a day (Table 4). The 
depression score, Geriatric Depression Scale, showed an inverse correlation (P=0.01), with 18.4% 
of the nondrinkers being classified as having moderate-to-severe depression, while they were only 
5.0% among those drinking ≥3 glasses a day (Table 4). All these differences were statistically 
significant after full adjustments (Table 4). 
Circulating Biomarkers 
Figure 2 shows the baseline levels of several circulating biomarkers related to cardiovascular 
function or inflammation, according to wine consumption. The plasma levels of osteoprotegerin, a 
member of the tumor necrosis factor superfamily, and of the endothelin precursor C-terminal 
proendothelin-1, a powerful endogenous vasoconstrictor, were inversely related to wine 
consumption (adjusted P<0.0001). A similar but less significant trend was observed for PTX3, a 
marker of vascular inflammation (P=0.01). The concentrations of 2 cardiac markers, N-terminal pro 
B-type natriuretic peptide and highsensitivity cardiac troponin T, tended to be lower in patients 
drinking ≥3 glasses of wine per day (P=0.04 and 0.002, respectively). 
Discussion 
In the whole population of patients with symptomatic chronic HF enrolled in the GISSI-HF trial, ≥2 
glasses of wine daily as assessed with a diet questionnaire, were associated to lower severity of HF, 
better perceived QoL, and more favorable profile of inflammatory circulating biomarkers. However, 
the multivariate analyses adjusted for patient’s characteristics abolished the relation of wine 
consumption with fatal and nonfatal clinical outcomes. 
Wine Consumption and Clinical Outcomes 
These Italian patients aged 67 years on the average, declared a low consumption of alcoholic 
beverages other than wine. This is consistent with the Italian culture, more so of elderly people. The 
neutral results on clinical outcomes should be compared with the existing data in HF because the 
largest study reported that light-to-moderate alcohol consumption was not associated with adverse 
outcomes in 6313 US patients with LV dysfunction, and even reduced the risk of fatal MI in 
patients with ischemic cause of HF.10 In 2231 patients from SAVE trial, with an LVEF <40% after 
MI, light-to-moderate alcohol intake did not alter the risk of hospitalization for HF.8 In 449 male 
US physicians with HF a J-shaped relation between alcohol intake and mortality was reported, so 
the risk was significantly lower only in those drinking 1 to 2 glasses per day.14 
In contrast, the study on 1332 Italian subjects aged ≥65 years found that alcohol consumption was 
associated with a 21% lower risk of death in subjects without HF, but a 29% higher risk of death in 
patients with chronic HF.15This study, the largest to date, supports a neutral effect of alcohol intake 
on the outcomes in chronic HF, after adjusting for several factors, including ischemic cause of HF. 
LVEF, and hypertension. A previous study from the GISSI collaboration showed that moderate 
wine intake, as collected with the same questionnaire, could even reduce cardiovascular events 
in patients after MI but substantially without overt HF.10 The reduction observed in GISSI 
Prevenzione was mainly because of a decrease in ischemic events such as incident MI, a potential 
target of wine protective action. In the placebo group of GISSI-HF, incident MI was only 0.7%, 
while worsening of HF was 9.5% and sudden death, presumably arrhythmic, 8.7%, thus reducing 
the potential benefits of wine.10 
Wine Consumption and Circulating Biomarkers 
In the subgroup of 1235 patients in whom circulating biomarkers were assayed, there was a 
consistent decrease in markers of inflammation with higher regular wine consumption even after 
adjustment for age, sex, and severity of HF. The independent association between wine 
consumption and markers of systemic inflammatory activation, known to play a role in chronic 
HF,31 has already been reported in different cardiovascular disorders.32,33 Moderate consumption 
of red wine and some of its compounds (particularly polyphenols) may confer protection in patients 
with documented cardiovascular disease. 5,6,9,10 Part of this benefit is because of an improvement 
of endothelial dysfunction through different molecular pathways that include enhanced endothelial 
nitric oxide production and vasodilatation, improved redox balance and anti-inflammatory 
mechanisms.34,35 Although circulating biomarkers cannot fully capture the complexity of 
paracrine regulations in the endothelium, we found that light-to-moderate wine consumption was 
associated with a dose-dependent reduction in the plasma concentration of a stable precursor of 
endothelin-1. This highly potent vasoconstrictor peptide, when elevated, is a strong predictor of bad 
outcome in chronic HF.24,36 Red wine extracts have been shown to inhibit endothelin-1 synthesis 
by bovine aortic endothelial cells,37 presumably by altering tyrosine–kinase signaling.38 
Polyphenols from red wine also blunt the expression of adhesion molecules and inflammatory 
cytokines related to endothelial dysfunction and atherosclerosis, contributing to a reduction in HF 
severity.7 Wine consumption, even light, was associated with lower plasma levels of 
osteoprotegerin and of PTX3 than in patients who did not drink wine. Osteoprotegerin is a cytokine 
of the tumor necrosis factor receptor superfamily, expressed in vivo by endothelial cells, vascular 
smooth muscle cells, and osteoblasts. Initially thought to act exclusively on the skeletal and 
immune system, more recent evidence suggests that it also hasa proatherogenic role and participates 
in the pathogenesis of cardiovascular diseases by amplifying the adverse effects of inflammation, 
hyperlipidemia, endothelial dysfunction, hypertension, and diabetes mellitus.39,40 PTX3 is rapidly 
induced in various cell subsets, such as peripheral blood leucocytes, myeloid dendritic cells, and 
vascular endothelium under the stimulation of inflammatory cytokines. PTX3 shares some 
similarities with CRP, but differs in terms of structural domain, gene organization, and cellular and 
tissue sources.41 In this context, high circulating osteoprotegerin and PTX3 levels might reflect an 
ongoing injury to endothelial cells, indicating a proinflammatory milieu. Together with the 
reduction in plasma endothelin concentration, this suggests that light-to-moderatewine consumption 
is associated with an improvement in endothelial dysfunction in patients with chronic HF. However, 
the pathophysiologic relevance of an anti-inflammatory action of moderate wine consumption 
should be seen in the light of the fact that in GISSI-HF we found that circulating inflammatory 
markers had little if any independent prognostic value23,27 and that rosuvastatin significantly 
decreased high-sensitivity C-reactive protein levels without affecting outcomes.18 
Finally, although statistically significant, the trend between N-terminal pro B-type natriuretic 
peptide or high-sensitivity cardiac troponin T and red wine consumption was not clear as for other 
biomarkers. This is consistent with the absence of any independent relation between red wine intake 
and clinical outcome. 
Wine Consumption, QoL, and Depression 
The evidences on the benefits of wine consumption are scarce to date, as the medical literature is 
mainly focused on the unhealthy consequences of alcohol drinking. Moderate wine drinkers 
reported better lifestyles and metabolic parameters compared with nondrinkers,42 lower incidence 
of HF,3 lower mortality,43 and a better perceived health43–45 and psychological functioning.46 
The differences remained statistically significant after adjustment for several variables, and even 
within populations of the same social class.43 This is the first time that such an association is 
reported in patients with chronic HF: in the 1465 patients in the QoL, depression, and cognitive 
function substudy, depression of moderate-to-high severity was significantly less frequent in 
patients drinking at least 1 glass of wine a day. The perception of health status, as assessed by 
Kansas City Cardiomyopathy Questionnaire, was significantly better in the same patients even after 
full adjustments. Our results are not easily comparable with other studies on general populations of 
Northern European countries, with different habits toward alcohol consumption and where wine 
drinking may be associated to a higher social background.42,43,46 Social class is not a confounder 
in our population because wine consumption is widespread and only a minority of patients drank 
beer or other spirits. The list of other potential confounders may include smoking, exercise, and 
social networks. However, Poikolainen et al45 reported that despite these adjustments, the 
associations between wine consumption and perceived health remained, weakening the role of 
lifestyles. In other studies, a good perception of health was independently associated with lower 
mortality in patients with HF,19 and depression overall,47 specifically major depression,48 was 
independently associated with a higher risk of cardiovascular and all-cause mortality. Moderate 
wine consumption is strongly associated with both favorable prognostic factors. Although we did 
not observe benefits on mortality or hospitalizations, we neither observed negative effects on health 
in moderate wine drinkers, highlighting that it is not necessarily a negative habit. Whether it is the 
wine consumption per se— and not the characteristics of the people who decide to drink wine, to 
account for the differences in health perception—is not clear. Because of the strength of the 
association, wine consumption could be a possible indicator of better attitude toward life, and not a 
behavior to be necessarily blamed in patients with HF. 
Some limitations need to be pointed out. The dietary questionnaire used in the GISSI-HF trial did 
not distinguish between red and white wine, 2 beverages whose content in biologically active 
compounds may differ, although the differences in the cardiovascular effects of the 2 kinds of wine 
have been questioned.49 For this reason, data from GISSI-HF cannot be easily compared with other 
populations with different types and patterns of alcohol consumption. In addition, the design of the 
clinical trial did not permit any causal relationship but only associations between patient-reported 
wine consumption and health status, which may be influenced by unreported confounding clinical 
variables. The patient characteristics were typical of those found in randomized clinical trials 
because in the general population, patients with HF are older, more often women, and more 
frequently with preserved LVEF. 
Generated by a large and well-documented population of patients with HF, with the support of 2 
complementary sets of the soft data on the QoL and circulating biomarkers, our findings do provide 
a reasonably consistent and comprehensive view of this old problem of cardiology. 
Among the various protective or risk factors which characterize HF, wine does not seem to play 
either a beneficial nor a dangerous role. Across the levels of exposure, wine seems more as 
descriptive variable which accompanies the more relevant hard determinants of health/risk: a 
critical clinical condition is a cause of nonexposure, or the expression of a multifactorial exposure 
to risks, including tobacco; low to moderate consumption could be part of a positive attitude to life 
consistent with the corresponding estimates of QoL. 
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Table 1: Baseline characteristics of 6,973 patients enrolled in the GISSI-HF trial, in relation to wine consumption. 
   


















Patients’ characteristics       
Age (years) 67 (11) 66 (11) 68 (10) 67 (10) 67 (11) 0.01 
Age > 70 years 1060 (43.1) 499 (37.7) 1152 (44.8) 236 (38.3) 2947 (42.3) 0.93 
Women 880 (35.8) 332 (25.1) 297 (11.6) 7 (1.1) 1516 (21.7) <0.0001 
Heart disease risk factors       
BMI (kg/m2) 27 (5) 27 (4) 27 (4) 27 (4) 27 (4) 0.004 
SBP (mm Hg) 127 (18) 125 (18) 126 (18) 128 (18) 126 (18) 0.90 
DBP (mm Hg) 77 (9) 76 (10) 77 (9) 79 (10) 77 (10) 0.10 
Heart rate (beats per min) 73 (14) 72 (14) 72 (14) 73 (15) 73 (14) 0.002 
Current smoking 308 (12.5) 181 (13.7) 363 (14.1) 134 (21.7) 986 (14.1) <0.0001 
History of hypertension 1421 (57.7) 698 (52.7) 1377 (53.6) 313 (50.7) 3809 (54.6) 0.0003 
NYHA class      <0.0001 
 II 1439 (58.5) 855 (64.5) 1698 (66.1) 431 (69.9) 4423 (63.4)  
 III 929 (37.8) 442 (33.4) 819 (31.9) 175 (28.4) 2365 (33.9)  
 IV 93 (3.8) 28 (2.1) 53 (2.1) 11 (1.8) 185 (2.7)  
LVEF (%) 33.3 (8.9) 32.7 (8.3) 32.9 (8.2) 33.5 (8.4) 33.1 (8.5) 0.69 
LVEF > 40% 255 (10.4) 112 (8.5) 222 (8.6) 64 (10.4) 653 (9.4) 0.21 
Medical history       
Admission for HF in previous year 1319 (53.6) 613 (46.3) 1191 (46.3) 260 (42.1) 3383 (48.5) <0.0001 
Previous AMI 985 (40.0) 599 (45.2) 1100 (42.8) 223 (36.1) 2907 (41.7) 0.98 
Previous stroke 135 (5.5) 59 (4.5) 129 (5.0) 22 (3.6) 345 (5.0) 0.12 
Diabetes mellitus 805 (32.7) 386 (29.1) 655 (25.5) 127 (20.6) 1973 (28.3) <0.0001 
CABG 382 (15.5) 250 (18.9) 528 (20.5) 110 (17.8) 1270 (18.2) 0.0002 
PCI 300 (12.2) 196 (14.8) 310 (12.1) 60 (9.7) 866 (12.4) 0.19 
ICD 166 (6.8) 122 (9.2) 172 (6.7) 37 (6.0) 497 (7.1) 0.47 
Pacemaker 319 (13.0) 178 (13.4) 324 (12.6) 70 (11.4) 891 (12.8) 0.35 
History of atrial fibrillation 462 (18.8) 255 (19.3) 496 (19.3) 111 (18.0) 1324 (19.0) 0.98 
Peripheral vascular disease 219 (8.9) 105 (7.9) 220 (8.6) 66 (10.7) 610 (8.8) 0.52 
COPD 528 (21.5) 249 (18.8) 578 (22.5) 178 (28.9) 1533 (22.0) 0.002 
Neoplasia 79 (3.2) 46 (3.5) 102 (4.0) 29 (4.7) 256 (3.7) 0.048 
Cause of heart failure       
Ischemic 1197 (48.6) 709 (53.5) 1282 (49.9) 278 (45.1) 3466 (49.7) 0.53 
Dilative 703 (28.6) 349 (26.3) 787 (30.6) 186 (30.2) 2025 (29.0) 0.09 
Hypertensive 393 (16.0) 185 (14.0) 369 (14.4) 89 (14.4) 1036 (14.9) 0.13 
Other 77 (3.1) 39 (2.9) 50 (2.0) 29 (4.7) 195 (2.8) 0.64 
Non-detectable/unknown 91 (3.7) 43 (3.3) 82 (3.2) 35 (5.7) 251 (3.6) 0.42 
Physical examination       
Pulmonary rales 715 (29.1) 301 (22.7) 608 (23.7) 145 (23.5) 1769 (25.4) <0.0001 
Third heart sound 655 (26.6) 328 (24.8) 601 (23.4) 153 (24.8) 1737 (24.9) 0.02 
Mitral insufficiency 1608 (65.3) 849 (64.1) 1610 (62.7) 343 (55.6) 4410 (63.2) <0.0001 
Aortic stenosis 55 (2.2) 24 (1.8) 55 (2.1) 9 (1.5) 143 (2.1) 0.43 
ECG findings       
QRS > 120 ms 824 (33.5) 445 (33.6) 903 (35.1) 207 (33.6) 2379 (34.1) 0.39 
Atrial fibrillation 390 (15.9) 189 (14.3) 458 (17.8) 102 (16.5) 1139 (16.3) 0.09 
Pathological Q waves 538 (21.9) 325 (24.5) 605 (23.5) 136 (22.0) 1604 (23.0) 0.40 
Left ventricular hypertrophy 455 (18.5) 219 (16.5) 537 (20.9) 127 (20.6) 1338 (19.2) 0.02 
Laboratory tests       
Fibrinogen (mg/dL) 376 (107) 379 (113) 364 (109) 351 (106) 370 (109) <0.0001 
WBC (/mm3) 7384 (2158) 7464 (2123) 7291 (2045) 7254 (2134) 7353 (2109) 0.05 
Serum creatinine (mg/dL) 1.20 (0.59) 1.20 (0.43) 1.21 (0.43) 1.14 (0.34) 1.20 (0.48) 0.21 
eGFR (mL*min-1*1.73m-2) 63 (23) 64 (22) 64 (21) 70 (20) 64 (22) <0.0001 
Serum bilirubin (mg/dL) 0.84 (0.64) 0.83 (0.56) 0.84 (0.50) 0.93 (0.91) 0.85 (0.61) 0.02 
AST (U/L) 25 (31) 24 (12) 24 (14) 26 (15) 24 (21) 0.92 
Hemoglobin (mg/dL) 13.4 (1.7) 13.6 (1.6) 13.9 (1.6) 14.3 (1.5) 13.7 (1.7) <0.0001 
Total cholesterol (mg/dL) 189 (43) 189 (42) 191 (42) 201 (45) 191 (43) <0.0001 
Serum HDL-cholesterol (mg/dL) 46 (12) 46 (13) 48 (13) 51 (15) 47 (13) <0.0001 
Blood glucose (mg/dL) 121 (48) 121 (51) 116 (43) 114 (37) 119 (46) <0.0001 
Medical treatment       
ACE inhibitors 1860 (75.6) 988 (74.6) 2014 (78.4) 511 (82.8) 5373 (77.1) <0.0001 
ARBs 484 (19.7) 291 (22.0) 463 (18.0) 82 (13.3) 1320 (18.9) 0.0008 
ACE inhibitors/ARBs 2293 (93.2) 1233 (93.1) 2415 (94.0) 577 (93.5) 6518 (93.5) 0.33 
Β blockers 1590 (64.6) 906 (68.4) 1635 (63.6) 390 (63.2) 4521 (64.8) 0.26 
Spironolactone 1004 (40.8) 534 (40.3) 968 (37.7) 233 (37.8) 2739 (39.3) 0.02 
Diuretic drugs 2247 (91.3) 1179 (89.0) 2303 (89.6) 530 (85.9) 6259 (89.8) 0.0005 
Digitalis 990 (40.2) 469 (35.4) 930 (36.2) 198 (32.1) 2587 (37.1) <0.0001 
Oral anticoagulant drugs 667 (27.1) 374 (28.2) 793 (30.9) 174 (28.2) 2008 (28.8) 0.02 
Aspirin 1165 (47.3) 647 (48.8) 1235 (48.1) 310 (50.2) 3357 (48.1) 0.31 
Other antiplatelet agents 285 (11.6) 138 (10.4) 244 (9.5) 49 (7.9) 716 (10.3) 0.002 
Nitrates 909 (36.9) 468 (35.3) 905 (35.2) 190 (30.8) 2472 (35.5) 0.01 
Calcium-channel blockers 267 (10.9) 133 (10.0) 240 (9.3) 69 (11.2) 709 (10.2) 0.32 
Amiodarone 436 (17.7) 270 (20.4) 536 (20.9) 116 (18.8) 1358 (19.5) 0.04 
Statin (open) 570 (23.2) 306 (23.1) 560 (21.8) 141 (22.9) 1577 (22.6) 0.37 
 
Continuous variables are reported as mean (SD), discrete variables as numbers (%) of patients for 
which the variable was present, percentages may not add up to 100 because of missing values or 
rounding. P for trend <0.05 for differences across categories of wine consumption. ACE indicates 
angiotensin-converting enzyme; AMI Acute myocardial Infarction; ARB, angiotensin II type 1 
receptor blocker; AST, aspartate aminotransferase; BMI, body-mass index; CABG, coronary artery 
bypass graft surgery; COPD, chronic obstructive pulmonary disease; DBP/SBP, diastolic/systolic 
blood pressure; eGFR, estimated glomerular filtration rate; HDL; High Density lipoprotein; HF, 
heart failure; ICD, implantable cardioverter defibrillator; LFEF, left ventricular ejection fraction; 
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; WBC, white blood 
cells. 
Table 2: Clinical outcomes during follow-up by levels of wine consumption 
 













Causes of death     
All causes 716 (29.1) 350 (26.4) 752 (29.3) 150 (24.3) 
Worsening HF 231 (9.4) 126 (9.5) 244 (9.5) 50 (8.1) 
Presumed arrhythmic 204 (8.3) 107 (8.1) 224 (8.7) 43 (7.0) 
CV death 523 (21.3) 274 (20.7) 572 (22.3) 108 (17.5) 
Sudden death 222 (9.0) 121 (9.1) 240 (9.3) 49 (7.9) 
Hospitalization     
All causes 1368 (55.6) 775 (58.5) 1492 (58.1) 378 (61.3) 
CV reasons 1127 (45.8) 663 (50.0) 1239 (48.2) 292 (47.3) 
HF 685 (27.8) 384 (29.0) 739 (28.8) 165 (26.7) 
Ventricular arrhythmias 59 (2.4) 53 (4.0) 96 (3.7) 20 (3.2) 
Total events     
All cause death or 
hospitalization for CV causes 
1413 (57.4) 781 (58.9) 1489 (57.9) 350 (56.7) 
Total MI 85 (3.5) 47 (3.6) 89 (3.5) 15 (2.4) 
Total stroke 86 (3.5) 46 (3.5) 75 (2.9) 18 (2.9) 
Total HF 718 (29.2) 394 (29.7) 761 (29.6) 170 (27.6) 
Total arrhythmias* 255 (10.4) 151 (11.4) 308 (12.0) 60 (9.7) 
 
Data are reported as number and percentage of the 6,973 patients. Total events include both fatal 
and non-fatal events. CV indicates cardiovascular; HF heart failure; and MI Myocardial Infarction. 




Data are shown as hazard ratio and 95% confidence interval in univariate and multivariable Cox 
proportional hazard models, with patients never drinkers as the reference category. 
Covariates for adjustment: age, sex, body mass index, ischemic etiology, NYHA class, admission 
for HF in the previous year, prior stroke, smoking, history of hypertension, diabetes, ICD, 
peripheral vascular disease, COPD, peripheral edema, pulmonary congestion, aortic stenosis, left 
ventricular ejection fraction, heart rate, systolic and diastolic blood pressure, pathological Q waves, 
atrial fibrillation, left ventricular hypertrophy, hemoglobin, total cholesterol, triglycerides, blood 
glucose, glomerular filtration rate, serum potassium, serum sodium, total creatine kinase, glycated 
hemoglobin, digitalis, spironolactone, diuretics, ARBs, β-blockers, oral anticoagulants, 
antiplatelets, nitrates, amiodarone, antidepressants, n-3 PUFA and statins. 
  















Unadjusted 0.89 [0.79-1.02] 1.00 [0.91-1.11] 0.79 [0.66-0.94] 0.18 0.04  
Fully adjusted 0.91 [0.80-1.03] 0.96 [0.86-1.07] 0.91 [0.76-1.09] 0.31 0.29  
All cause death or 
hospitalization for 
CV causes 
Unadjusted 1.04 [0.96-1.14] 1.00 [0.93-1.08] 0.93 [0.82-1.04] 0.42 0.22  
Fully adjusted 1.07 [0.98-1.17] 1.01 [0.94-1.09] 1.04 [0.92-1.18] 0.64 0.30  
Worsening HF 
Unadjusted 1.03 [0.91-1.17] 1.03 [0.92-1.14] 0.90 [0.76-1.06] 0.62 0.89  
Fully adjusted 1.06 [0.94-1.21] 1.08 [0.97-1.21] 1.12 [0.94-1.34] 0.11 0.94  
Sudden death 
Unadjusted 1.00 [0.80-1.24] 1.03 [0.86-1.24] 0.83 [0.61-1.14] 0.66 0.53  
Fully adjusted 0.99 [0.79-1.24] 0.98 [0.81-1.19] 0.90 [0.65-1.24] 0.63 0.79  

















Good (≥75) 822 (56.1) 225 (46.0) 173 (57.5) 347 (62.6) 77 (63.6) 
<0.0001 
Fair (74-50) 413 (28.2) 161 (32.9) 77 (25.6) 140 (25.3) 35 (28.9) 
Poor (25-49) 185 (12.6) 74 (15.1) 43 (14.3) 59 (10.6) 9 (7.4) 
Worst (<25) 45 (3.1) 29 (5.9) 8 (2.7) 8 (1.4) 0 (0.0) 
Median [IR] 78.6 [59.9-
90.6] 
72.4 [52.9-87.5] 80.2 [59.9-89.2] 82.3 [64.8-92.7] 82.3 [70.3-94.8] <0.0001§ 
Depression (GDS score) 
None (0-4) 970 (66.2) 290 (59.3) 198 (65.8) 390 (70.4) 92 (76.0) 
<0.0122 
Mild (5-8) 310 (21.2) 109 (22.3) 72 (23.9) 106 (19.1) 23 (19.0) 
Moderate/severe 
(≥9) 
185 (12.6) 90 (18.4) 31 (10.3) 58 (10.5) 6 (5.0) 
Median [IR] 3 [1-6] 3 [1-7] 3 [1-6] 2 [1-5] 2 [1-4] <0.002§ 
 
GDS indicates Geriatric Depression Scale and KCCQ, Kansas City Cardiomyopathy Questionnaire 
*Adjusted for age, sex, body mass index, ischemic causes of HF, NYHA class, admission for HF in 
the previous year, previous stroke, smoking, history of hypertension, diabetes mellitus, Implantable, 
cardioverter defibrillator, peripheral vascular disease, chronic obstructive pulmonary disease, 
peripheral edema, pulmonary congestion, aortic stenosis, left ventricular ejection fraction, heart 
rate, systolic and diastolic blood pressure, pathological Q waves, atrial fibrillation, left ventricular 
hypertrophy, hemoglobin, total cholesterol, triglycerides, blood glucose, glomerular filtration rate, 
serum potassium, serum sodium, total creatine kinase, glycated hemoglobin, digitalis, 
spironolactone, diuretics, ARBs, β-blockers, oral anticoagulants, antiplatelets, nitrates, amiodarone, 
antidepressants, polinstured fatty acids and rosuvastatin. 




Figure 2. Median (Q1-Q3)plasma concentrations of selected circulating biomarkers in relation to 
wine consumption in 1235 patients with chronic heart failure from the Gruppo Italiano per lo Studio 
della Sopravvivenza per l’Insufficienza Cardiaca-Heart Failure study. P values adjusted for age, sex 
and NYHA class. Multiple regression model  on the ranks of the biomarkers adjusted  for age, sex 
and NYHA functional class. CT-proET-1, C-terminal proendothelin-1; hs-cTnT, high-sensitivity 




Figure 1. Adjustment survival curves for (A) all-cause mortality, (B) all-cause mortality or 
hospitalization for cardiovascular (CV) reasons by 4 categories of wine consumption. The variables 
used for adjustment are listed below table 3. 
 
 
 
